Corcept Therapeutics Incorporated
CORT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.15 | 4.30 | -10.37 | 3.74 |
| FCF Yield | 3.77% | 3.77% | 5.53% | 7.31% |
| EV / EBITDA | 36.74 | 29.80 | 15.22 | 15.28 |
| Quality | ||||
| ROIC | 17.09% | 17.68% | 19.50% | 26.81% |
| Gross Margin | 98.39% | 98.66% | 98.66% | 98.56% |
| Cash Conversion Ratio | 1.40 | 1.20 | 1.19 | 1.49 |
| Growth | ||||
| Revenue 3-Year CAGR | 18.87% | 9.64% | 4.33% | 6.09% |
| Free Cash Flow Growth | 54.37% | 5.83% | -28.38% | 11.07% |
| Safety | ||||
| Net Debt / EBITDA | -0.87 | -1.25 | -3.82 | -2.62 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.88 | 0.84 | 0.32 | 0.29 |
| Cash Conversion Cycle | -70.23 | -502.66 | 383.56 | 790.73 |